On July 16, 2024, David Gurzick represented FAST and the A-BOM at the 4th Chief Patient Officer’s Summit on a panel focused on Cell and Gene Therapy trials. The goal was to offer insight that can inform better trials for when companies advance AS trials to the clinic.
The chief patient officer is a role that’s now quite prevalent in pharma. That said, it’s a role that is still being defined, and the individuals in this role are often the most direct connection between patients and their needs clinical trials.
For this conference, the 4th Chief Patient Officer’s Summit, David was in a panel that sought to inform the Chief Patient Officer’s and others in the room on both the pragmatics of involving patients and caregivers across all aspects of clinical trials - including their design, logistics, and management - and to stress the value that comes from integrating patients and caregivers in ways beyond just being participants.
They had a specific focus on Cell and Gene Therapy trials; hopefully we offered insight that can inform better trials for when any of these companies (or the companies that the members in the room might work with) advance AS trials to the clinic.
David represented FAST and the goals of A-BOM, a leader in the creation and design of drug development tools, which represent an aspect of clinical trial design. As a parent, he also brought a deep understanding of the situational context being a caregiver to someone with who might one day participate in these trials and who could offer advice on how these trials can best be designed to meet the needs of our community.